fr   en
Acquisitions
Select a company :
Choose date:
«      1   |   2   |   3   |   4   |   5   |   6   |   7   |   8   |   9   |   10      »      
Date Acquiring pharma company Acquired biotech company Amount Terms / other
2009-12-16 Silence Therapeutics (UK) Intradigm (USA)   See details
2009-12-14 Qiagen (The Netherlands) SABiosciences (USA) US$90 million in cash (€61.8 million) See details
2009-11-23 Pfizer (USA) assets related to stem cell therapies from Axordia (UK - Intercytex's wholly owned subsidiary) $750,000 See details
2009-11-18 Cosmo Pharmaceuticals (Italy) BioXell (Italy) CHF 41.3 million (€ 27.4 million) See details
2009-11-16 TiGenix (Belgium) Orthomimetics (UK) €16 million ($ 23.8 million) See details
2009-11-12 Biota (Australia) antibacterial assets of Prolysis (UK) Under the terms of the agreement, Biota will acquire the key assets and programs for:
- $A10.8 million (£6.4million ) as Biota ordinary shares, of which 60% will be subject to a 12 month escrow period;
- the ability to receive up to a 15% share in all milestone and royalties earned on commercialisation with Biota retaining all upfront payments on licensed programs.
See details
2009-11-05 Agennix (USA) GPC Biotech (Germany)   See details
2009-11-03 Lonza (Switzerland) Algonomics (Belgium) The purchase price was not disclosed. See details
2009-10-30 Proximagen Neuroscience (UK) Cambridge Biotechnology Ltd (UK - Swedish Biovitrum's wholly-owned subsidiary) Detailed financial terms of the deal are not being disclosed.
CBT will be acquired on a cash free/debt free basis and has not generated any third party revenues.
See details
2009-10-23 Eurogentec (Belgium) Anaspec (USA) undisclosed See details
2009-10-13 Lonza (Switzerland) Simbiosys Bioawares India (India) Financial details were not disclosed. See details
2009-10-01 Sanofi-Aventis (France) Fovea Pharmaceutical (France) €370 millions, including an immediate upfront payment and subsequent milestone payments related to the three clinical compounds.
See details
2009-09-28 Abbott (USA) Solvay Pharmaceuticals (Belgium) €5.2 billion including purchase price of €4.5 billion in cash and additional potential payments of up to €300 million if certain milestones are met between 2011 and 2013.
It also includes the assumption of certain liabilities, which Solvay today values at approximately €400 million.
See details
2009-09-23 Qiagen (The Netherlands) DxS Ltd (UK) US$ 95 million in cash (subject to customary purchase price adjustments), plus up to an additional US$ 35 million if specified commercial and other milestones are met. See details
2009-09-18 Evolva (Switzerland) Arpida (Switzerland)   See details
«      1   |   2   |   3   |   4   |   5   |   6   |   7   |   8   |   9   |   10      »